Lymphoma News

CHICAGO — Second-line therapy with axicabtagene ciloleucel conferred a significant increase in OS compared with the current standard of care among adults with relapsed or refractory large B-cell lymphoma, results of the randomized phase 3 ZUMA-7 study showed.

CHICAGO — The addition of nivolumab vs. brentuximab vedotin to AVD chemotherapy significantly reduced the risk for disease progression and disease-related death among adults with previously untreated advanced classic Hodgkin lymphoma.

CHICAGO — During ASCO Annual Meeting, Healio honored our Healio Disruptive Innovators in hematology/oncology in our second annual award ceremony.

In this video interview, Brian Hill, MD, PhD, Director of the Lymphoid Malignancies Program at the Cleveland Clinic Taussig Cancer Institute discusses recent FDA approvals in Lymphoma treatment and care.

In this video interview, Brian Hill, MD, PhD, Director of the Lymphoid Malignancies Program at the Cleveland Clinic Taussig Cancer Institute discusses factors that may keep patients from necessary DLBCL care.

In this video interview, Brian Hill, MD, PhD, Director of the Lymphoid Malignancies Program at the Cleveland Clinic Taussig Cancer Institute emphasizes need for consistent type of care of DLBCL patients who do not go into remission.

In this video interview, Brian Hill, MD, PhD, Director of the Lymphoid Malignancies Program at the Cleveland Clinic Taussig Cancer Institute discusses the use of cellular therapy in patients with relapsed/refractory Lymphoma.

In a video interview, Brian Hill, MD, PhD, Director of the Lymphoid Malignancies Program at the Cleveland Clinic Taussig Cancer Institute discusses who benefits from awareness surrounding DLBCL.

The FDA granted accelerated approval to epcoritamab-bysp for treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, according to the agent’s manufacturer.

Primary endpoints of randomized clinical trials for cancer therapies frequently change after trial initiation, according to findings published in JAMA Network Open.